



Aaron Kruler

Contact information	<ul style="list-style-type: none">• Av Medrano 134 piso 6 Caba. Bs As. Argentina. Zip. code C1179AAB.• Phone 054 011 4983 1589.• Email: iantuc@hotmail.com
Education	<ul style="list-style-type: none">• Medical, National University of Tucumán.2008.• Specialist in Internal Medicine, National University of Bs. As, 2014• Specialization in nutrition, Universidad Católica Argentina, 2013.• Complete residency in diabetes. Malvinas Argentinas. 2014• Master's degree in diabetes Universidad del Salvador. 2014• Diplomat in Advanced Healing of Wounds AIACH-UAI. 2017.• Provision 6677/10 ANMAT, LATAM, Jun 2019.• Good clinical practices, Eli Lilly 2019. (last current update)• Good clinical practice, The Global Health Network, Oct 2021.• Diploma in Good Practices in Biomedical Research. University of San Pablo.Tucumán. August 2020 to July 2021 (238 hours).
Current employment information	<ul style="list-style-type: none">• Investigaciones Médicas IMOBA SRL Av Medrano 134 floor 6 CABA Medical investigator from 2019 until today.• Centro de diabetes Dr. Maggio Malvinas Argentinas Residency instructor in diabetology and diabetes clinic oriented to the diabetic foot. From 2010 until today.• Blossom Weliness, Grupo Proyecto. Centro Integral de atención al Diabético. From 2014 until today.• Corporación Médica de San Martin. Consultorio de diabetes y Nutrición. From 2015 until.
License	<ul style="list-style-type: none">• MN 129181• MP 58481
Clinical studies in the last 5 years	

- K-877-302 Prominent Pemafibrate to reduce cardiovascular outcomes by lowering triglycerides in patients with diabetes. From 2019 to the present. Phase III. Quintiles. Sub investigator
- I8F-MC-GPGM Efficacy and safety of Ly3298176 once a week vs insulin glargine in patients with type 2 diabetes and high cardiovascular risk. From February 2020 to July 2021. Phase III. Eli Lilly. Sub investigator
- I8F-MC-GPGH: Phase 3 open-label, randomized study comparing the effect of LY3298176 vs titrated insulin Degludec on the glycemic control of pts. with type 2 diabetes. Eli Lilly. From July 2019 to April 2021. Phase III. Eli Lilly. Sub investigator
- I8F-MC-GPGL: Randomized, open-label, phase 3 trial, comparing the efficiency and safety of Tirzepatide vs Semaglutide once a week as an add-on therapy to metformin in patients with type 2 DBT. Eli Lilly. From 2019 to April 2021. Phase III. Eli Lilly.
- LPS15017: Premix, phase 3 study to compare Lixi match with insulin mix in ptes with type 2 DBT. Sanofi Aventis. From 2019 to 2020. Sanofi. Phase III. Sub Investigator
- — LPS15396 / ARTEMIS-DM: A multicenter, multinational, prospective, interventional, single-arm phase IV study evaluating the clinical efficacy and safety of 26 weeks of treatment with insulin glargine 300 U / ml (Gla-300) in patients with type 2 diabetes mellitus not controlled with basal insulin. From 2019 to 2020 . Sanofi Aventis. Sub Investigator
- I8H-MC-BDCL A Phase 2 parallel, comparator- Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin- Native with Type 2 Diabetes Mellitus. Eli Lilly. Sub Investigator From Nov 2020 to present.
- I8F-MC-GPHM Efficacy and SAfefty of Tirzepatide Once Weekly vs Placebo after an intensive Lifestyle Program participants without Type 2 Diabetes who have Obesiy or are Overweight with weight- related Comorbidities: Randomized Double Blind, Placebo Controlled Trial. Sub Investigator. From April 2021 to present.
- I8F-MC-GPHD Arandomized, phase 3, open label Trial comparing the effect of the addition of tirzepatide once weekly vs insulin lispro (U100) Three times

	daily in participants with type 2 diabetes inadequately controlled on insulin glargine (U100) with or without metformin. Sub Investigator. From Dec 2020 to present.
--	--

Signature:

Date: